Daewoong Pharmaceutical's NABOTA®, sets foot in the Philippines

NABOTA®, is the latest Clostridium Botulinum Toxin Type A that boasts of High Purity which makes it safe. Its stability leads to longer shelf life. Compared to the existing brands, NABOTA® has faster effect and longer duration. Developed from bio-technology of over 30 years of know-how and manufactured from Daewoong’s world class GMP, NABOTA® is widely accepted to more than 90 countries worldwide including US and European Union nations.

The NABOTA® Philippine Launch was actually historic as this is the first time that all 7 societies from the field of aesthetic medicine (Phil. Dermatological Society, Phil. Academy of Dermatologic Surgery Foundation, Phil. Assn. of Plastic and Reconstructive Surgery, Phil. Academy of Clinical & Cosmetic Dermatology, Phil. Academy of Aesthetic and Age-Management Medicine Inc., Phil. Association of Primary Skin Health Physicians, Inc., Phil. Academy of Aesthetic Surgery) supported the event alongside more than 500 doctors.

Daewoong Pharmaceutical Co., Ltd. has the largest prescription drug sales in Korea and envisions itself to become a top 50 global healthcare company for 2015.

In the Philippines, NABOTA® is exclusively marketed by Daewoong Pharma Phils. Inc. under the leadership of its experienced Brand Manager Christopher Cachuela who has been promoting dermatology products for more than 10 years. Daewoong Phils has successfully registered and launched over 37 brands in the market.
With NABOTA® entering the Philippine market, Filipinos can now achieve natural beauty safely and effectively.